Baseline characteristics of the 141 patients
Variable . | ALL patients . |
|---|---|
| Age | |
| Median, y | 58 |
| Range, y | 19-80 |
| No. 60 y or older (%) | 65 (46) |
| Sex, no. (%) | |
| Male | 77 (55) |
| Female | 64 (45) |
| Initial drug dose, no. (%) | |
| Less than 400 mg | 7 (5) |
| 400 mg | 123 (87) |
| More than 400 mg | 11 (8) |
| Response to IFN, no. (%) | |
| Hematologic failure | 46 (33) |
| Cytogenetic failure | 35 (25) |
| Intolerance | 60 (42) |
| Drug dose escalation, no. (%) | |
| Yes | 35 (25) |
| No | 106 (75) |
| Enlarged spleen, no. (%) | |
| Yes | 46 (33) |
| No | 95 (67) |
| WBC count, × 109/L | |
| Median | 16.2 |
| Range | 1.3-175.9 |
| Platelet count, × 109/L | |
| Median | 339 |
| Range | 46-168 |
| Hemoglobin level, g/L | |
| Median | 125 |
| Range | 33-163 |
| Basophils, % | |
| Median | 3 |
| Range | 0-26 |
| Time since diagnosis, mo | |
| Median | 35.6 |
| Range | 0-1145.2 |
| Duration of previous IFN therapy, mo | |
| Median | 13 |
| Interquartile range | 6-25 |
| Patients who previously received a stem cell transplant, no. (%) | |
| Yes | 9 (6) |
| No | 132 (94) |
| Clonal evolution, no. (%) | |
| Yes | 22 (16) |
| No | 119 (84) |
| Follow-up time, mo | |
| Median | 15.9 |
| Range | 1.8-47.2 |
Variable . | ALL patients . |
|---|---|
| Age | |
| Median, y | 58 |
| Range, y | 19-80 |
| No. 60 y or older (%) | 65 (46) |
| Sex, no. (%) | |
| Male | 77 (55) |
| Female | 64 (45) |
| Initial drug dose, no. (%) | |
| Less than 400 mg | 7 (5) |
| 400 mg | 123 (87) |
| More than 400 mg | 11 (8) |
| Response to IFN, no. (%) | |
| Hematologic failure | 46 (33) |
| Cytogenetic failure | 35 (25) |
| Intolerance | 60 (42) |
| Drug dose escalation, no. (%) | |
| Yes | 35 (25) |
| No | 106 (75) |
| Enlarged spleen, no. (%) | |
| Yes | 46 (33) |
| No | 95 (67) |
| WBC count, × 109/L | |
| Median | 16.2 |
| Range | 1.3-175.9 |
| Platelet count, × 109/L | |
| Median | 339 |
| Range | 46-168 |
| Hemoglobin level, g/L | |
| Median | 125 |
| Range | 33-163 |
| Basophils, % | |
| Median | 3 |
| Range | 0-26 |
| Time since diagnosis, mo | |
| Median | 35.6 |
| Range | 0-1145.2 |
| Duration of previous IFN therapy, mo | |
| Median | 13 |
| Interquartile range | 6-25 |
| Patients who previously received a stem cell transplant, no. (%) | |
| Yes | 9 (6) |
| No | 132 (94) |
| Clonal evolution, no. (%) | |
| Yes | 22 (16) |
| No | 119 (84) |
| Follow-up time, mo | |
| Median | 15.9 |
| Range | 1.8-47.2 |